S100A1 and cancer: Extensive evidence suggests that the deregulated expression of S100 proteins is closely linked to tumor progression and drug resistance in the treatment of many malignant tumors, including ovarian cancer [4], breast cancer [5], prostate cancer [6], and colorectal cancer [7].